245 related articles for article (PubMed ID: 7691978)
21. [The 5HT3-receptor antagonist Zofran (ondansetron) as an agent for preventing nausea and vomiting during the cytostatic treatment of cancer patients].
Perevodchikova NI; Volkova MA; Gorbunova VA; Manziuk LV; Marenich AF; Smirnova NB
Ter Arkh; 1996; 68(2):30-4. PubMed ID: 8771653
[TBL] [Abstract][Full Text] [Related]
22. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Rubenstein EB
Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
[TBL] [Abstract][Full Text] [Related]
23. [The management of vomiting and nausea with zofran during the chemotherapy of malignant tumors].
Seliuzhitskiĭ IV; Eliseev SN; Ivanov AI
Voen Med Zh; 1994 Oct; (10):34-6. PubMed ID: 7831851
[No Abstract] [Full Text] [Related]
24. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
[TBL] [Abstract][Full Text] [Related]
25. 5-hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesis: can we safely reduce the dose of administered agents?
Aapro M; Blower P
Cancer; 2005 Jul; 104(1):1-18. PubMed ID: 15929119
[TBL] [Abstract][Full Text] [Related]
26. [Use of ondansetron, a 5-HT3 receptor antagonist, as a new type of antiemetic in pediatric oncology].
Csáki C; Ferencz T; Koós R; Schuler D; Borsi J
Orv Hetil; 1993 Jun; 134(25):1363-7. PubMed ID: 8332356
[TBL] [Abstract][Full Text] [Related]
27. [Ondansetron (GR 38032F), a competitive 5-HT3 receptor antagonist as an antiemetic in cytostatic drug-induced nausea and vomiting. An open, substance-oriented phase II/III study].
Serve H; Perker M; Ertl A; Reichold M; Fink U; Berdel WE
Onkologie; 1990 Oct; 13(5):369-74. PubMed ID: 2150552
[TBL] [Abstract][Full Text] [Related]
28. Use of intravenous microdialysis to monitor changes in serotonin release and metabolism induced by cisplatin in cancer patients: comparative effects of granisetron and ondansetron.
Castejon AM; Paez X; Hernandez L; Cubeddu LX
J Pharmacol Exp Ther; 1999 Dec; 291(3):960-6. PubMed ID: 10565811
[TBL] [Abstract][Full Text] [Related]
29. [Ondansetron in the prevention of radiation-induced nausea and emesis in patients treated with single-fraction irradiation].
Jeremić B
Srp Arh Celok Lek; 1996; 124(5-6):131-4. PubMed ID: 9102832
[TBL] [Abstract][Full Text] [Related]
30. The development of a protocol for the use of 5-HT3 antagonists in chemotherapy-induced nausea and vomiting.
Watters J; Riley M; Pedley I; Whitehead A; Overend M; Goss I; Allgar V
Clin Oncol (R Coll Radiol); 2001; 13(6):422-6. PubMed ID: 11824878
[TBL] [Abstract][Full Text] [Related]
31. [Clinical efficacy of GG032X tablets, a new dosage form of ondansetron (fast dispersing tablet), on cisplatin-induced nausea and emesis].
Ariyoshi Y; Nukariya N; Akasaka Y; Suminaga M; Ota J; Ikeda M; Taguchi T
Gan To Kagaku Ryoho; 1997 Jun; 24(8):995-1011. PubMed ID: 9212810
[TBL] [Abstract][Full Text] [Related]
32. Guidelines for the optimal management of chemotherapy-induced nausea and vomiting: a consensus.
Osoba D; Warr DG; Fitch MI; Nakashima L; Warren B
Can J Oncol; 1995 Sep; 5(3):381-400. PubMed ID: 8853513
[TBL] [Abstract][Full Text] [Related]
33. [Efficacy of combination of ondansetron injection and tablet in CAF-induced emesis in breast cancer patients].
Shinohara H; Yonekawa H; Machimura T; Furukawa T; Nishihori H; Kurihara N; Urakami H; Nemoto Y
Gan To Kagaku Ryoho; 1998 Feb; 25(3):397-402. PubMed ID: 9492834
[TBL] [Abstract][Full Text] [Related]
34. [Combined use of ondansetron and other anti-emetics to control cisplatin-induced nausea and vomiting].
Zeng WY
Zhonghua Zhong Liu Za Zhi; 1993 Mar; 15(2):118-21. PubMed ID: 8223120
[TBL] [Abstract][Full Text] [Related]
35. Comparison of the efficacy and safety of combinations of metopimazine or ondansetron with methylprednisolone in the prevention of delayed emesis in patients receiving chemotherapy.
Bloch J; Rixe O; Meric JB; Delgado A; Khayat D
Curr Med Res Opin; 2005 Nov; 21(11):1763-71. PubMed ID: 16307696
[TBL] [Abstract][Full Text] [Related]
36. Preliminary experience with use of a selective 5HT3 receptor antagonist (ondansetron) to prevent high dose chemotherapy induced emesis.
Parikh PM; Shah SR; Shah SC; Sheth V; Patel RA; Shah KC; Jain PK
Indian J Cancer; 1996 Mar; 33(1):17-20. PubMed ID: 9063013
[TBL] [Abstract][Full Text] [Related]
37. Granisetron and ondansetron for chemotherapy-related nausea and vomiting.
Zeidman A; Ben Dayan D; Ben Zion T; Kaufman O; Cohen AM; Mittelman M
Haematologia (Budap); 1998; 29(1):25-31. PubMed ID: 9704254
[TBL] [Abstract][Full Text] [Related]
38. Omission of day 2 of antiemetic medications is a cost saving strategy for improving chemotherapy-induced nausea and vomiting control: results of a randomized phase III trial.
Lajolo PP; de Camargo B; del Giglio A
Am J Clin Oncol; 2009 Feb; 32(1):23-6. PubMed ID: 19194119
[TBL] [Abstract][Full Text] [Related]
39. Efficacy, safety and effectiveness of ondansetron compared to other serotonin-3 receptor antagonists (5-HT3RAs) used to control chemotherapy-induced nausea and vomiting: systematic review and meta-analysis.
Simino GP; Marra LP; Andrade EI; Acúrcio Fde A; Reis IA; De Araújo VE; Cherchiglia ML
Expert Rev Clin Pharmacol; 2016 Sep; 9(9):1183-94. PubMed ID: 27180992
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of ondansetron in patients receiving cisplatin therapy.
Parr MD; McIntyre WJ; Henderson LM; MacDonald JS; Chandler MH
Clin Pharm; 1992 Dec; 11(12):1026-9. PubMed ID: 1286552
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
